HomeRIMEGEPANT

  • Biohaven to test Rimegepant as a preventive Migraine treatment as well

    • July 1, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ph 3 data for Rimegepant in Acute Migraine to be presented at AHC annual scientific meeting 2018

    • June 6, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Strong clinical data with single dose rimegepant in acute treatment of migraine announced by Biohaven

    • April 24, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Biohaven to present additional Phase 3 Rimegepant Data at AAN 2018

    • April 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Acute Migraine treatment Rimegepant successfully achieves Co-Primary Endpoints in two pivotal Phase 3 Trials

    • March 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Acute Migraine treatment ZYDIS® ODT enrolls first patient in Ph 3 clinical trial

    • March 21, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more